Lenalidomide Approved for Myeloma Maintenance After HSCT Lenalidomide Approved for Myeloma Maintenance After HSCT
Lenalidomide (Revlimid) gets the first-ever FDA approval for use in myeloma as a maintenance therapy after autologous stem cell transplant.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer & Oncology | Hematology | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Transplants